Tesamorelin 10 mg

Compound profile

Tesamorelin: compound profile, literature landscape and handling notes

Where Tesamorelin came from

Growth-hormone-releasing hormone was isolated in the early 1980s, and the circumstance of its isolation is worth remembering because it shaped everything that followed. The peptide was not first purified from hypothalamic tissue, which is available in vanishingly small quantities, but from pancreatic islet-cell tumors in patients who had developed acromegaly without a pituitary lesion. Those tumors were producing the hypothalamic releasing factor ectopically and in bulk, which gave two independent groups enough material to sequence. The 44-residue amidated form was identified as the full-length hormone, and shortly afterwards the N-terminal 1-29 fragment was shown to retain essentially full activity, which is where sermorelin comes from.

The practical problem with all of these was stability. Native GHRH has a plasma survival measured in minutes, not because of general proteolysis but because of one specific and very fast reaction at one specific bond, described in the structure section below. Two obvious strategies existed: substitute the residues around the cleavage site with non-natural amino acids, which is the route taken by the modified GHRH 1-29 constructs that circulate in this catalog under other names, or cap the N-terminus with an acyl group so that the aminopeptidase has nothing to grip. Tesamorelin, which appears in the early literature under the development code TH9507, took the second route and kept the full 44-residue backbone rather than truncating to 1-29.

The molecule was developed by a Canadian company and pushed through a clinical program aimed at excess visceral adipose tissue in people with HIV-associated body-composition changes, receiving United States regulatory approval for that indication in 2010. That history is the single most important thing to know about the reference base for this compound, because it means the literature grew top-down from a registration program rather than bottom-up from academic pharmacology. A research buyer should expect deep human endpoint data and shallow independent in vitro characterization, which is the reverse of the usual situation for a catalog peptide.

Reading the structure of Tesamorelin

The sequence, formula and mass for this listing are printed in the specification table further down this page and are not restated here. What matters is what the one structural departure from the native hormone is for, and why it sits where it does.

Dipeptidyl peptidase-4 removes dipeptides from the free N-terminus of substrates that present a small residue, alanine or proline, in the second position. Human GHRH presents tyrosine at position one and alanine at position two, which makes the Tyr1-Ala2 bond a textbook DPP-4 site. Cleavage yields the 3-44 fragment, and that fragment is not a partial agonist worth studying but a largely inert species that can still occupy assay space and confuse an immunoassay. So the enzymatic liability of native GHRH is not diffuse degradation, it is one reaction at one bond, and a design that blocks that single reaction buys most of the available stability.

Acylating the alpha-amino group of Tyr1 with trans-3-hexenoyl does exactly that: DPP-4 requires a free, protonatable N-terminal amine, and an amide-linked acyl group removes it. The choice of a short, modestly unsaturated six-carbon acyl rather than a long fatty acid is deliberate and is the point most often missed. The N-terminal region of GHRH is the activation domain, the part that inserts into the transmembrane bundle of the receptor to trigger signaling, so anything bulky there risks destroying agonist activity outright. A small hydrophobic cap is tolerated; a palmitoyl or stearoyl chain of the kind used on incretin analogs would not be, and in any case would recruit albumin binding and convert the molecule into a slow-release depot, which is contrary to the whole pharmacological premise here.

The consequence is that tesamorelin is a stabilized analog, not a long-acting one. Its published survival in circulation is longer than native GHRH but still on the order of minutes rather than hours or days. Everything else about the molecule is native human sequence: the same C-terminal amidation, the same mid-sequence methionine and asparagine residues that create the chemical liabilities discussed further down, and the same basic cluster near the C-terminus that dominates its behavior in ion-exchange and in tryptic digestion.

The target and the pathway in more detail

The GHRH receptor is a class B, secretin-family G-protein-coupled receptor expressed densely and almost exclusively on anterior pituitary somatotrophs. Its architecture follows the family pattern that also governs the incretin receptors: a large extracellular domain captures the C-terminal half of the ligand and holds it, while the ligand N-terminus swings into the transmembrane bundle and drives the conformational change that activates the receptor. This two-domain binding model is the structural reason the N-terminal modification described above is such a delicate piece of design, and it is also why the C-terminal half of GHRH tolerates truncation at residue 29 with little loss of affinity.

Coupling is primarily to Gs. Receptor occupancy raises adenylyl cyclase activity and intracellular cyclic AMP, activates protein kinase A, and produces two distinct outputs on two timescales. The fast output is exocytosis of stored growth hormone, which requires calcium entry through voltage-gated channels following PKA-dependent depolarization. The slow output is transcriptional: CREB phosphorylation, Pit-1 expression and growth hormone gene transcription, plus somatotroph proliferation. A GHRH-receptor agonist therefore does something a bolus of growth hormone cannot, which is act on both the releasable pool and the machinery that refills it. There are also reports of secondary phospholipase C coupling, and a splice variant of the receptor described in non-pituitary and tumor tissue, both of which are real but peripheral to the core pharmacology.

The pathway is not an open loop. Somatostatin provides opposing inhibitory tone at the same somatotroph through Gi-coupled receptors, and the alternation between somatostatin and GHRH tone is what makes endogenous growth hormone secretion pulsatile rather than continuous. Downstream, growth hormone acts on hepatic and peripheral growth hormone receptors through JAK2 and STAT5b to drive IGF-1 expression, and circulating IGF-1 feeds back to raise somatostatin tone and suppress somatotroph output. That intact feedback arc is what imposes a ceiling on any secretagogue, and it is the central conceptual difference between stimulating a gland and supplying its product.

The pulsatile-versus-continuous distinction dominates this literature for two reasons. At the receptor, sustained occupancy of a class B GPCR drives desensitization, internalization and downregulation, so a continuously present agonist progressively loses the ability to do what an intermittently present one does. Downstream, the pattern of growth hormone exposure, not just its integrated amount, determines which STAT5b-dependent gene programs are engaged; this is documented in detail in rodent liver, where continuous and pulsatile exposure produce recognizably different transcriptional profiles. Any experiment using a GHRH-receptor agonist that does not record the temporal pattern of exposure has discarded the variable the field considers most important.

What the published literature on Tesamorelin actually measures

The published tesamorelin record splits into three parts of very unequal size, and distinguishing them is more consequential here than for most compounds because a large fraction of secondary writing silently merges them.

The largest part is clinical, and it comes from the registration program and its extensions. The primary endpoints are imaging-based measurements of visceral adipose tissue area, with circulating IGF-1 tracked as the pharmacodynamic surrogate for target engagement. Later work in the same population extended to hepatic fat fraction and related metabolic endpoints. These are human outcome studies. They characterize what happened to people in a trial; they do not characterize the molecule, and they belong in the introduction of a bench protocol rather than in its methods.

The second part, and the one most useful at a bench, is the GHRH-receptor pharmacology literature that mostly predates tesamorelin. Cyclic AMP accumulation and growth hormone release from primary pituitary cell cultures and from somatotroph-derived lines, radioligand binding to the cloned human receptor, receptor desensitization time courses, and the physiology of somatostatin-GHRH alternation in vivo were all established using native GHRH 1-44, GHRH 1-29 and various substituted fragments. Tesamorelin inherits this framework, and most people who cite receptor-level parameters for tesamorelin are in fact citing parameters measured on a related GHRH species. That inheritance is usually reasonable, since the backbone is native, but it should be stated rather than assumed.

The third part is analytical and formulation work associated with manufacturing: stability-indicating chromatographic methods, degradation-product profiling, and the peptide-mapping approaches described in the analytical section below. This part is small, often appears in specialist analytical journals or in regulatory summaries rather than in pharmacology journals, and is easy to miss precisely because researchers searching for a peptide search pharmacology databases.

A fourth category is worth naming only so it can be excluded. A substantial amount of what circulates online as tesamorelin literature consists of conference abstracts, sponsor-authored summaries and secondary reviews that restate the same trial data. None of that is independent replication, and counting it as such badly inflates the apparent depth of the evidence base.

Where the Tesamorelin literature is thin or frequently misread

The honest summary is that tesamorelin has a deep clinical file and a shallow independent mechanistic one, and nearly every common misreading of the compound traces back to that imbalance.

The first and largest gap is independent bench characterization of tesamorelin as a distinct molecular entity. There is very little published work in which tesamorelin and unmodified GHRH 1-44 were run side by side in the same binding or cyclic AMP assay by a group with no stake in the outcome. The near-universal assumption that the hexenoyl cap is pharmacodynamically silent, altering only susceptibility to DPP-4, is plausible on structural grounds and consistent with the compound working at all, but it is an inference rather than a well-replicated measurement.

The second is the pulsatility claim. It is routinely stated that a GHRH-receptor agonist preserves the natural pulsatile pattern of growth hormone secretion while exogenous growth hormone does not. The mechanistic argument is sound, but demonstrating it requires frequent-sampling growth hormone profiles, and most of the clinical record uses a single IGF-1 measurement instead. IGF-1 is an integrated, slow, hepatically filtered surrogate that is blind to pulse architecture by construction. A claim about pulsatility supported only by an IGF-1 value is not supported.

The third is extrapolation across species. GHRH sequences diverge appreciably between human and rodent, more than is generally appreciated, and both the ligand and the receptor differ. Data generated with human GHRH analogs in rodent systems, and rodent findings imported to explain human observations, need the cross-species comparison stated explicitly rather than assumed.

The fourth is scope creep from one population to general physiology. The clinical program was conducted in a specific population with a specific metabolic phenotype, and the visceral-adipose findings there are frequently reported as if they were a general property of GHRH-receptor stimulation in any organism. They may or may not be; the studies that would establish that were not the studies that were run.

The fifth is smaller but persistent: exploratory work on other endpoints, including cognitive measures in older adults, is genuinely interesting and genuinely small, single-center, and underpowered for the conclusions frequently drawn from it.

How Tesamorelin behaves in solution

Tesamorelin is supplied as lyophilized material, and unlike the acylated incretin analogs elsewhere in this catalog it is not a surfactant. The hexenoyl cap is far too small to make the molecule amphiphilic in the micelle-forming sense, so its solution behavior is that of an ordinary mid-size polar peptide rather than that of a fatty-acid conjugate. That does not make it well behaved, only differently behaved.

Adsorption to container surfaces is still the dominant practical loss route at low concentration. A roughly five-kilodalton peptide with a mixed charge distribution and a basic cluster near the C-terminus will bind to untreated glass and to some plastics, and the fraction lost scales with surface-area-to-volume ratio, so dilute working solutions in large tubes are where material disappears. Low-binding labware, minimized transfer steps and minimized headspace all help.

Chemically the liabilities are the ones the native sequence already carries. Asparagine residues followed by small flexible neighbors undergo deamidation through a succinimide intermediate, a reaction that accelerates sharply above neutral pH and with temperature; it adds a single mass unit and a negative charge, so a deamidated preparation looks nearly identical by intact mass and quite different by ion exchange. The same intermediate produces isoaspartate, which is invisible to most routine methods. The single mid-sequence methionine is an oxidation target, sensitive to trace peroxide in buffers and to metal ions. The alkene in the hexenoyl group is in principle a further oxidation and isomerization site, though this is not something the published record characterizes in any detail, and it is a reasonable argument for keeping working solutions out of direct light.

Aggregation is the failure mode that ends an experiment rather than merely biasing it. Interfaces drive it, which makes vigorous mixing and repeated freeze-thaw cycling the two things most worth avoiding. Aliquot once at a concentration you will actually work at rather than returning repeatedly to a stock. A degraded solution sometimes announces itself as faint opalescence or as fine wisps visible when the vial is tilted against a dark background, but the more common and more dangerous case is quiet loss of active material with no visual change at all. The storage statement in the specification table above is the product record for this material and should be read against the documentation supplied with the lot.

Analytical notes specific to Tesamorelin

At 44 residues tesamorelin sits in an awkward analytical size range: too large for the single-charge, single-peak simplicity of a short peptide, too small for the workflows built around proteins. Electrospray ionization produces a multiply charged envelope rather than one dominant ion, and the reported observed mass is a deconvolution across that envelope. When comparing an observed mass against a calculated one, confirm both are the same kind of figure, monoisotopic against monoisotopic or average against average, because at this mass the gap between them exceeds the tolerance many certificates state.

The specific trap for this molecule is that the identifying modification is small. A trans-3-hexenoyl group adds well under a hundred mass units to a five-kilodalton backbone, which is a fractionally tiny shift. An intact-mass measurement with a loose tolerance, or one performed on a low-resolution instrument, can fail to distinguish capped from uncapped material, and uncapped material is not tesamorelin. This is the single most important reason that peptide mapping, rather than intact mass alone, is the informative identity test here.

Tryptic digestion works well because the sequence carries several arginine and lysine residues, but two features deserve attention. The basic cluster toward the C-terminus generates very short fragments that can be lost at the desalting step or elute in the void, so sequence coverage should be checked rather than assumed, and a second protease with orthogonal specificity is often worth running for the C-terminal region. More importantly, the N-terminal tryptic peptide is the one that carries the hexenoyl label, so that peptide, and MS/MS fragmentation of it, is where the modification is actually confirmed and localized. Localization matters because acylation on the tyrosine phenolic oxygen rather than the alpha-amino nitrogen would be isobaric at the intact level and pharmacologically meaningless, and only fragmentation distinguishes them.

Ultraviolet quantitation deserves a specific warning. The sequence contains no tryptophan and only a pair of tyrosines, so absorbance at 280 nanometers is weak and a poor basis for concentration. Peptide-bond absorbance near 214 nanometers against a matched standard, amino acid analysis, or quantitative nitrogen determination are all better answers. Reversed-phase separation should use a shallow gradient, since the capped and uncapped forms differ by only modest hydrophobicity and elute close together, as do the deamidated variants. Peptide content, meaning how much of the labeled mass is peptide rather than counter-ion and residual water, is a separate measurement from both purity and identity and is the one most often missing.

Compounds researchers confuse with Tesamorelin

Questions specific to Tesamorelin